Bilateral breast cancer: Differential diagnosis using histological and biological parameters

Japanese Journal of Clinical Oncology

Volumn 37, Issue 7, 2007, Pages 487-492

  Gong, Soo Jung ^a   Rha, Sun Young ^b   Jeung, Hei Cheul ^b   Roh, Jae Kyung ^b   Yang, Woo Ick ^c   Chung, Hyun Cheol ^b  

^a Eulji University School of Medicine   (South Korea)

^b Yonsei University College of Medicine   (South Korea)

^c Yonsei University College of Medicine   (South Korea)

Author keywords

Bilateral breast cancer; Biomarker; Histology

Indexed keywords

BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ARTICLE; BILATERAL CANCER; BREAST CANCER; CANCER GRADING; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRADUCTAL CARCINOMA; METASTASIS; PROTEIN EXPRESSION; SECOND CANCER; STATISTICAL SIGNIFICANCE;

ADULT; AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, MULTIPLE PRIMARY; NEOPLASMS, SECOND PRIMARY; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE;

EID: 34548332530     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hym056     Document Type: Article

References (31)

1. Dawson LA, Chow E, Goss PE. Evolving perspectives in contralateral breast cancer. Eur J Cancer 1998;34:2000-9
2. Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, et al. Bilateral risk for subsequent breast cancer after lobular carcinoma in-situ: Analysis of surveillance epidemiology and end results data J Clin Oncol 2005;23:5534-41
3. Chaudary MA, Millis RR, Hoskins EOL, Halder M, Bulbrook RD, Bilateral breast cancer: A prospective study of disease incidence. Br J Surg 1984;71:711-4
4. Takahashi H, Watanabe K, Takahashi M, Taguchi K, Sasaki F, Todo S, The impact of bilateral breast cancer on the prognosis of breast cancer: A comparative study with unilateral breast cancer. Breast Cancer 2005;12:196-20
5. Levi F, Randimbison L, Te VC, La Vecchia C, Prognosis of bilateral synchronous breast cancer in Vaud Switzerland. The Breast 2003;12:89-91
6. Carmichael AR, Bendall S, Lockerbie L, Prescott R, Bates T, The long-term outcome of synchronous bilateral breast cancer is worse than metachronous or unilateral tumours. Eur J Surg Oncol 2002;28:388-91
7. Kollias J, Ellis IO, Elston CW, Blamey RW, Prognostic signicance of synchronous and metachronous bilateral breast cancer. World J Surg 2001;25:1117-24
8. Mose S, Adamietz IA, Thilmann C, Saran F, Bernhard M, Pahnke R, et al. Bilateral breast carcinoma versus unilateral disease. Review of 498 patients. Am J Clin Oncol 1997;20:541-5
9. Deo SV, Shridhar D, Purkayastha J, Bhutani M, Shukla NK, Raina V, Therapeutic controversies in bilateral breast cancer. Clin Oncol (R Coll Radiol) 2003;15:297-8
10. Seo MY, Rha SY, Yang SH, Kim SC, Lee GY, Park CH, et al. The pattern of gene copy number changes in bilateral breast cancer surveyed by cDNA microarray-based comparative genomic hybridization. Int J Mol Med 2004;13:17-24
11. Intra M, Rotmensz N, Viale G, Mariani L, Bonanni B, Mastropasqua MG, et al. Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institution. Cancer 2004;101:905-12
12. de la Rochefordiere A, Asselain B, Scholl S, Campana F, Ucla L, Vilcoq JR, et al. Simultaneous bilateral breast carcinomas: A retrospecitve review of 149 cases. Int J Radiat Oncol Biol Phys 1994;30:35-41
13. Brankovic-Magic M, Nikolic-Vukosavljevic D, Neskovic-Konstantinovic Z, Kanjer K, Spuzic I. Estrogen and progesterone receptor content in bilateral breast cancer. Pathol Res Pract 1995;191:16-24
14. Hahnel R, Twaddle E. The relationship between estrogen receptors in primary and secondary breast carcinomas and in sequential primary breast carcinoma. Breast Cancer Res Treat 1985;5:155-63
15. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10
16. Shi SR, Cote RJ, Chaiwun B, Young LL, Shi Y, Hawes D, et al. Standardization of immunohistochemistry based on antigen retrieval technique for routine formalin-fixed tissue sections. Appl Immunohistochem 1998;6:89-96
17. Layfield LJ, Gupta D, Mooney EE. Assessment of tissue estrogen and progesterone receptor levels: A survey of current practice, techniques, and quantitation methods. Breast J 2000;6:189-96
18. Hanna W, Kahn HJ, Trudeau M. Evaluation of HER-2/neu(erbB-2) status in breast cancer: From bench to bedside. Mol Pathol 1999;12:827-34
19. Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual New York: Springer-Verlag 2002;257-81
20. Son BH, Kwak BS, Kim JK, Kim HJ, Hong SJ, Lee JS. et al. Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years. Arch Surg 2006;141:155-60
21. Dickson RB, Pestell RG, Lippman ME. Molecular biology of breast cancer. In DeVita VT, Hellman S, Rosenberg SA, editors Cancer: Principles & Practice of Oncology Philadelphia PA: Lippincott Williams & Wilkins 2005;1399-414
22. Colleoni M, Rotmensz N, Robertson C, Orlando L, Viale G, Renne G, et al. Very young women (35 years) with operable breast cancer: Features of disease at presentation. Ann Oncol 2002;13:273-9
23. Arpino G, Weiss HL, Clark GM, Hilsenbeck SG, Osborne CK. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen. J Clin Oncol 2005;23:4687-94
24. Swain SM, Wilson JW, Mamounas EP, Bryant J, Wickerham DL, Fisher B, et al. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516-23
25. Cavaliere A, Bellezza G, Scheibel M, Vitali R, Sidoni A, Biopathological prole of multiple synchronous homolateral and bilateral breast cancers. Pathol Res Pract 2004;200:9-12
26. Matsuo K, Fukutomi T, Akashi-Tanaka S, Hasegawa T, Tsuda H. Histological grade p53 HER2 and hormone receptor status of synchronous bilateral breast carcinoma. Breast Cancer 2002;9:127-33
27. Matsuo K, Fukutomi T, Tsuda H, Akashi-Tanaka S, Shimizu C, Hasegawa T. Differences in estrogen receptor status HER2 and p53 comparing metachronous bilateral breast carcinoma. J Surg Oncol 2001;77:31-4
28. Kinoshita T, Ueda M, Enomoto K, Lkeda T, Kikuchi K, Ishii S, et al. Comparison of p53 gene abnormalities in bilateral and unilateral breast cancer. Cancer 1995;76:2504-9
29. Safal M, Lower EE, Hasselgren PO, Hungness ES, Gazder P, Aron B, et al. Bilateral synchronous breast cancer and HER-2/neu overexpression. Breast Cancer Res Treat 2002;72:195-201
30. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998;34:791-808
31. van Agthoven T, Timmermans M, Dorssers LC, Henzen-Logmans SC. Expression of estrogen, progesterone and epidermal growth factor receptor in primary and metastatic breast cancer. Int J Cancer 1995;63:790-3